China Pharma Holdings (CPHI) EBITDA Margin Growth (3y) (2013 - 2026)
Powered by 
Analysis
China Pharma Holdings (CPHI) EBITDA Margin Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 120.00 |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 531.00 |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 3,082.00 |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 842.00 |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 214.00 |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -963.00 |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 2,139.00 |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | -1,031.00 |
| 10 | China Pharma Holdings | 31.39 Mn | 31.08 Mn | 83,566.00 | -10,942.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -10,942.00 |
| Mar 31, 2026 | -9,332.00 |
| Dec 31, 2025 | -5,787.00 |
| Sep 30, 2025 | -4,803.00 |
| Jun 30, 2025 | -1,525.00 |
| Mar 31, 2025 | -992.00 |
| Dec 31, 2024 | -8,302.00 |
| Sep 30, 2024 | -6,011.00 |
| Jun 30, 2024 | -11,927.00 |
| Mar 31, 2024 | -3,734.00 |
| Dec 31, 2023 | -1,752.00 |
| Sep 30, 2023 | 11.00 |
| Jun 30, 2023 | -4,355.00 |
| Mar 31, 2023 | 1,370.00 |
| Dec 31, 2022 | 57,261.00 |
| Sep 30, 2022 | -788.00 |
| Jun 30, 2022 | -1,902.00 |
| Mar 31, 2022 | -4,543.00 |
| Dec 31, 2021 | 20,917.00 |
| Sep 30, 2021 | 4,550.00 |